Contemporary outcomes of long-term anticoagulation in COVID-19 patients: a regression matched sensitivity analysis of the national inpatient sample

References

• Bradbury CA, McQuilten Z. Anticoagulation in COVID-19. Lancet. 2022;399(10319):5–7. doi: 10.1016/S0140-6736(21)02503-4
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–2973. doi: 10.1016/j.jacc.2020.04.031
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Bradbury C, Abrams ST, et al. COVID-19 and immunothrombosis: emerging understanding and clinical management. Br J Haematol. 2021;194(3):518–529. doi: 10.1111/bjh.17664
   PubMed Web of Science ®Google Scholar
• Piazza G, Diagnosis MD. Management, and pathophysiology of arterial and venous thrombosis in COVID-19. JAMA. 2020;324(24):2548–2549. doi: 10.1001/jama.2020.23422
   PubMed Web of Science ®Google Scholar
• Boonyawat K, Chantrathammachart P, Numthavaj P, et al. Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Thrombosis J. 2020;18(1):34. doi: 10.1186/s12959-020-00248-5
   PubMed Web of Science ®Google Scholar
• Jenner WJ, Gorog DA. Incidence of thrombotic complications in COVID-19. J Thromb Thrombolysis. 2021;52(4):999–1006. doi: 10.1007/s11239-021-02475-7
   PubMed Web of Science ®Google Scholar
• Gomez K, Laffan M, Bradbury C. Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVID‐19 while we are awaiting the results of clinical trials? Br J Haematol. 2021;192(3):459. doi: 10.1111/bjh.17241
   PubMed Web of Science ®Google Scholar
• Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020;136(11):1347–1350. doi: 10.1182/blood.2020008086
   PubMed Web of Science ®Google Scholar
• ATTACC Investigators. ACTIV-4a Investigators; REMAP-CAP Investigators, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021;385(9):790–802. doi: 10.1056/NEJMoa2105911
   PubMed Web of Science ®Google Scholar
• REMAP-CAP Investigators. ACTIV-4a Investigators; ATTACC investigators, et al. therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med. 2021;385(9):777–789. doi: 10.1056/NEJMoa2103417
   PubMed Web of Science ®Google Scholar
• Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:2400. doi: 10.1136/bmj.n2400
   Google Scholar
• HCUP National Inpatient Sample (NIS): Healthcare Cost and Utilization Project (HCUP). Rockville MD: Agency for Healthcare Research and Quality; 2012. www.hcup-us.ahrq.gov/nisoverview.jsp
   Google Scholar
• Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med care. 1998;36(1):8–27. doi: 10.1097/00005650-199801000-00004
   PubMed Web of Science ®Google Scholar
• StataCorp. Stata Statistical Software: release 17. College Station TX: StataCorp LLC; 2021.
   Google Scholar
• Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020;7(5):e362–e363. doi: 10.1016/S2352-3026(20)30109-5
   PubMed Web of Science ®Google Scholar
• Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 Infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e7. doi: 10.1016/j.cell.2020.04.004
   PubMed Web of Science ®Google Scholar
• Abou-Ismail MY, Diamond A, Kapoor S, et al. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. 2020;194:101–115. doi: 10.1016/j.thromres.2020.06.029
   PubMed Web of Science ®Google Scholar
• *Rossi R, Coppi F, Talarico M, et al. Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. Eur J Intern Med. 2020;77:158–160.
   PubMed Web of Science ®Google Scholar
• Harrison RF, Forte K, Buscher MG Jr, et al. The association of preinfection daily oral anticoagulation use and all-cause in hospital mortality from novel coronavirus 2019 at 21 days: a retrospective cohort study. Crit Care Explor. 2021;3(1):e0324. doi: 10.1097/CCE.0000000000000324
   PubMedGoogle Scholar
• Denas G, Gennaro N, Ferroni E, et al. Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study. Int J Cardiol. 2021;329:266–269.
   PubMed Web of Science ®Google Scholar
• Fröhlich GM, Jeschke E, Eichler U, et al. Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany. Clin Res Cardiol. 2021;110(7):1041–1050. doi: 10.1007/s00392-020-01783-x
   PubMed Web of Science ®Google Scholar
• Flam B, Wintzell V, Ludvigsson JF, et al. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med. 2021;289(3):411–419. doi: 10.1111/joim.13205
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Buckley BJR, Harrison SL, et al. Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thromb Res. 2021;205:1–7. doi: 10.1016/j.thromres.2021.06.014
   PubMed Web of Science ®Google Scholar
• Montorfano M, Leoni O, Andreassi A, et al. Chronic anticoagulant treatment and risk of mortality in SARS-Cov2 patients: a large population-based study. Minerva Med. 2022. doi: 10.23736/S0026-4806.22.07797-7
   PubMedGoogle Scholar
• Nguyen NT, Chinn J, Nahmias J, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open. 2021;4(3):e210417. doi: 10.1001/jamanetworkopen.2021.0417
   PubMed Web of Science ®Google Scholar
• Sandoval Y, Januzzi JL Jr, Jaffe AS. Cardiac Troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week. Journal Of The American College Of Cardiology. 2020;76(10):1244–1258. doi: 10.1016/j.jacc.2020.06.068
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612–1620. doi: 10.1001/jamainternmed.2021.6203
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017;117(7):1448–1454. doi: 10.1160/TH16-12-0961
   PubMed Web of Science ®Google Scholar
• Cools F, Johnson D, Camm AJ, et al. Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry. J Thromb Haemost. 2021;19(9):2322–2334. doi: 10.1111/jth.15415
   PubMed Web of Science ®Google Scholar
• Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639. doi: 10.1016/j.eclinm.2020.100639
   PubMedGoogle Scholar
• Speed V, Patel RK, Byrne R, et al. A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic. Thromb Res. 2020;192:73–74. doi: 10.1016/j.thromres.2020.05.024
   PubMed Web of Science ®Google Scholar
• Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels’ striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. J Thromb Haemost. 2020;18(6):1320–1323. doi: 10.1111/jth.14871
   PubMed Web of Science ®Google Scholar
• Potere N, Candeloro M, Porreca E, et al. Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone. J Thromb Thrombolysis. 2022;53(2):346–351. doi: 10.1007/s11239-021-02561-w
   PubMed Web of Science ®Google Scholar
• Testa S, Paoletti O, Giorgi-Pierfranceschi M, et al. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med. 2020;15(5):751–753. doi: 10.1007/s11739-020-02331-1
   PubMed Web of Science ®Google Scholar
• Tritschler T, Mathieu ME, Skeith L, et al. Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost. 2020;18(11):2958–2967. doi: 10.1111/jth.15094
   PubMed Web of Science ®Google Scholar